We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
-0.11%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$7.97B
AUM Growth
-$817M
Cap. Flow
-$41.1M
Cap. Flow %
-0.52%
Top 10 Hldgs %
77.13%
Holding
94
New
12
Increased
15
Reduced
7
Closed
7

Top Buys

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$71.2M
2
BCYC
Bicycle Therapeutics
BCYC
+$67M
3
EWTX icon
Edgewise Therapeutics
EWTX
+$43.3M
4
ABCL icon
AbCellera Biologics
ABCL
+$23.6M
5
DNLI icon
Denali Therapeutics
DNLI
+$21.1M

Top Sells

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$242M
2
IMCR icon
Immunocore
IMCR
+$69M
3
GRCL
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
+$20.9M
4
DAWN
Day One Biopharmaceuticals
DAWN
+$14.6M
5
SPRY icon
ARS Pharmaceuticals
SPRY
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 99.96%
2 Financials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACHL
76
DELISTED
Achilles Therapeutics
ACHL
$1.51M 0.02%
1,208,775
-894,017
-43% -$964K
GBIO
77
DELISTED
Generation Bio
GBIO
$1.51M 0.02%
+37,122
New +$874K
MURA
78
DELISTED
Mural Oncology
MURA
$1.09M 0.01%
+222,503
New +$1.08M
PFE icon
79
Pfizer
PFE
$160B
$971K 0.01%
35,000
– –
TARA icon
80
Protara Therapeutics
TARA
$228M
$801K 0.01%
199,671
– –
PMVP icon
81
PMV Pharmaceuticals
PMVP
$71.1M
$547K 0.01%
322,024
– –
ACRV icon
82
Acrivon Therapeutics
ACRV
$94.7M
$378K ﹤0.01%
+52,885
New +$245K
FHTX icon
83
Foghorn Therapeutics
FHTX
$420M
$302K ﹤0.01%
45,027
– –
CABA icon
84
Cabaletta Bio
CABA
$531M
$227K ﹤0.01%
13,331
– –
CATX icon
85
Perspective Therapeutics
CATX
$377M
$178K ﹤0.01%
14,979
-748,991
-98% -$6.39M
TYRA icon
86
Tyra Biosciences
TYRA
$1.55B
$174K ﹤0.01%
10,607
– –
SRZNW
87
DELISTED
Surrozen Inc Warrant
SRZNW
$25.2K ﹤0.01%
833,333
– –
DAWN
88
DELISTED
Day One Biopharmaceuticals
DAWN
– –
-1,000,000
Closed -$14.6M
SPRY icon
89
ARS Pharmaceuticals
SPRY
$547M
– –
-2,006,451
Closed -$11M
WHWK
90
Whitehawk Therapeutics
WHWK
$270M
– –
-251,727
Closed -$508K
BCEL
91
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
– –
-2,177,499
Closed -$287K
GRCL
92
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
– –
-2,080,000
Closed -$20.9M
NVTA
93
DELISTED
Invitae Corporation
NVTA
– –
-1,764,546
Closed -$1.11M
MRTX
94
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-4,121,440
Closed -$242M
1 2 3
4

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q1 2024 Portfolio in Review

As of Q1 2024, Julian Baker held 94 positions worth $7.97B, down 9.3% from $8.79B the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Julian Baker's Q1 2024 filing shows 12 new, 15 increased, 7 reduced and 7 closed positions. Its largest new stake was Fate Therapeutics: 1,818,181 shares worth $13.3M. The largest sale was Mirati Therapeutics, Inc. Common Stock, an estimated $242M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 98% a quarter earlier, followed by Financials.

  • Julian Baker's largest Q1 2024 buy was Fate Therapeutics: 1,818,181 shares worth $13.3M.
  • Julian Baker added most to Revolution Medicines in Q1 2024, an estimated $71.2M increase.
  • Julian Baker's biggest Q1 2024 reduction was Immunocore, cutting an estimated $69M.
  • Julian Baker fully exited Mirati Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $242M.
  • Julian Baker's ten largest holdings make up 77% of its $7.97B portfolio in Q1 2024.
  • Julian Baker opened 12 new positions and closed 7 in Q1 2024.
  • Julian Baker's portfolio value fell 9.3% quarter-over-quarter to $7.97B.

Based on Baker Bros. Advisors's 13F filing for Q1 2024, filed 15 May 2024.